IDEAYA Biosciences presented late-breaking Phase 1 expansion results for IDE397, a first-in-class, oral MAT2A inhibitor, at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain. The data showcased the drug's potential in treating urothelial and non-small cell lung cancer (NSCLC) patients with methylthioadenosine phosphorylase (MTAP) deletions.
IDE397 Phase 1 Expansion Results
Dr. Benjamin Herzberg, Assistant Professor at Columbia University, presented the findings, which focused on the efficacy and safety of IDE397 in MTAP-deleted NSCLC and urothelial cancer. The study is designed to evaluate IDE397's impact on tumors characterized by MTAP deletions, a genetic vulnerability prevalent in various cancers. MTAP deletion leads to accumulation of methylthioadenosine (MTA), creating a dependency that MAT2A inhibitors like IDE397 can exploit.
Additional Preclinical Data
In addition to the IDE397 presentation, IDEAYA also presented preclinical data for its MAT2A and PARG programs. One poster highlighted the mechanistic basis for antitumor activity through combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors. Another poster presentation featured IDE161, a potential first-in-class PARG inhibitor, selectively targeting solid tumors with replication stress and DNA repair vulnerabilities.
IDEAYA's Precision Medicine Approach
IDEAYA Biosciences is committed to discovering and developing targeted therapeutics for patient populations selected using molecular diagnostics. Their approach integrates identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality, which represents an emerging class of precision medicine targets.
